OneSource Specialty Pharma Reaffirms FY28 Guidance After Typo Correction in Q3FY26 Results

OneSource Specialty Pharma Ltd. has corrected a typographical error in their Q3FY26 results press release, which was disseminated to stock exchanges on January 23, 2026. The error was in the paragraph with the heading 'FY 28 Guidance Reaffirmation' on the first page, where they had inadvertently mentioned '$400 million in organic revenue and $500 million including recently proposed acquisitions' instead of '$400 million in organic revenue and $500 million including recently proposed acquisitions'. The corrected press release does not impact the financials or disclosures made therein. Despite the delayed semaglutide approvals in Canada, the company's nascent biologics segment has shown strong interest, with another global biosimilar player onboarded and the funnel at a historic high.